

Table 3. Comparison of the general characteristics of the patients and the staining rates of VEGF, PDGFR-B and Thrombospondin-1

	VEGF (0-1) n (%)	VEGF (2-3) n (%)	p	PDGFR (0-1) n (%)	PDGFR (2-3) n (%)	p	Thrombospondin (0-1) n (%)	Thrombospondin (2-3) n (%)	p
Gender (female/male)	17 (56.7)/ 13 (43.3)	3 (21.4)/ 11 (78.6)	0.029	13 (40.6)/ 19 (59.4)	7 (58.3)/ 5 (41.7)	0.477	20 (48.8)/ 21 (51.2)	0 (0)/ 3 (100)	0.377
IPI			0.419			0.332			0,558
<3	16 (53.3)	10 (71.4)		17 (53.1)	9 (75)		25 (61)	1(33,3)	
≥3	14 (46.7)	4 (28.6)		15 (46.9)	3 (25)		16 (39)	2(66,7)	
B symptoms in diagnosis	17 (56.7)	8 (57.1)	1.00	19 (59.4)	6 (50)	0.828	22 (53,7)	3 (100)	0,247
Stage			0.596						0.599
≤2	13(43,3)	8(57.1)		14(43.7)	7(58.3)	0,601	19(46.3)	2(66.7)	
>2	17(56,7)	6(42.9)		18(56.3)	5(41.7)		22(53.7)	1(33.3)	
Bone marrow involvement in diagnosis	3 (10)	1 (7.1)	1.00	3 (9.4)	1 (8.3)	1.000	4 (9.8)	0 (0)	1.000

Hepatomegal y in diagnosis	6 (20)	0 (0)	0,155	5 (15.6)	1 (8.3)	1.000	6 (14.6)	0 (0)	1.000
Splenomegaly in diagnosis	8 (26.7)	3 (21.4)	1.000	7 (21.9)	4 (33.3)	0.457	10 (24.4)	1 (33.3)	1.000
Bulky disease in diagnosis	2 (6.7)	3 (21.4)	0,307	4 (12.5)	1 (8.3)	1.000	5 (12.2)	0 (0)	1.000
Extranodal involvement in diagnosis	7 (23.3)	1 (7.1)	0.402	7(21.9)	1 (8.3)	0.403	8 (19.5)	0 (0)	1.000
Refractory disease	3 (10)	1 (8.3)	1.000	4 (12.9)	0 (0)	0.563	4 (10)	0 (0)	1.000
Relapse on follow-up	3 (10)	2 (15.4)	0,630	3 (9.7)	2 (16.7)	0.608	5 (12,5)	0 (0)	1.000

